Published in final edited form as:

J Org Chem. 2012 April 6; 77(7): 3651–3657. doi:10.1021/jo3001723.

Transmissive Olefination Route to Putative “Morinol I” Lignans

Lihua Yao[†], Bhaskar Pitta[‡], P. C. Ravikumar[§], Matthew Purzycki, and Fraser F. Fleming^{*}

Department of Chemistry and Biochemistry, Duquesne University, Pittsburgh, Pennsylvania 15282-1530

Abstract

A series of morinol-type lignans were rapidly assembled using a Grignard-based transmissive olefination. In combination with palladium-catalyzed arylations, the strategy provides stereoselective access to (7*Z*, 7'*E*), (7*E*, 7'*E*), (7*E*, 7'*Z*) morinol diastereomers and the (7*Z*, 8'*E*) and (7*E*, 8'*E*) conjugated analogs. Critical for the *E/Z*-stereoselectivity is a new, general method for converting alkenenitriles to alkenemethanols that circumvents the enal *E/Z* isomerization commonly encountered during conventional *i*-Bu₂AlH reduction.

Alkenenitrile pharmacophores are embedded within an array of pharmaceuticals¹ and natural products² (Figure 1). In many instances the nitrile plays a key role in receptor binding as with the potent anti-HIV agent³ rilpivirine (**1**) where the nitrile groups interact deep within the binding pocket.⁴ Consistent with the key role of the nitrile group, *E/Z*-alkenenitrile diastereomers often exhibit significantly different potencies as exemplified by the antitumor agent **2**.⁵ A similar interplay of substitution and *E/Z*-geometry influences the antitumor activity⁶ of calyculins A-H (**3**), unusual *E*- and *Z*-tetraenenitriles from the marine sponges *Discodermia calyx* and *Lamellomorpha strongylata*.²

Selective access to diastereomeric *E*- and *Z*-alkenenitriles is challenging.⁷ In addressing this challenge, a stereoselective synthesis of *Z*-alkenenitriles **6** was developed that hinges on an intramolecular transmissive olefination through a highly ordered transition structure (Scheme 1).⁸ Addition of excess Grignard reagent to Baylis-Hilman-derived⁹ hydroxyalkenenitriles **4** triggers a displacement that selectively affords *Z*-alkenenitriles **6**. Mechanistic probes are consistent with a concerted reorganization through the magnesiate **5** in which the slender¹⁰ nitrile group preferentially eclipses the carbinol substituent R¹.

Rapid access to *Z*-alkenenitriles from three readily available components, an aldehyde, acrylonitrile, and a Grignard reagent, appeared ideal for synthesizing, and unraveling the

flemingf@duq.edu.

[†]Mylan Pharmaceuticals Inc., 781 Chestnut Ridge Rd., Morgantown, WV 26505.

[‡]Biophore Pharmaceuticals, Prashant Nagar, Kukatpally, Hyderabad AP 500 0072, India.

[§]School of Basic Sciences, Indian Institute of Technology, Mandi, HP 175001, India.

Supporting Information Available. ¹H NMR and ¹³C NMR spectra for all new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

structural ambiguity of, the neolignan morinol I. Morinol I is one of a series of neolignans¹¹ (Figure 2, **8-19**) that were isolated during a bioactivity guided isolation of extracts from the roots of the traditional Chinese medicinal herb *Morina chinensis*.¹² Among morinol metabolites the proposed structure **7** for morinol I is unique in having a skipped diene. All morinols, except morinol I, formally have water added to the C7-C8 bond. The related neolignan galanganal (**15**), isolated from the Zingiberaceae plant *Alpinia galangal*, has the same olefin position as **7** but the opposite C7 alkene geometry.¹³

Intriguingly, the HMBC and NOESY correlations reported for morinol I are not consistent with the skipped diene structure **7** but require a conjugated C7-C8 C9'-C8' diene. Adding to the structural ambiguity is the secure structural identification of morinols A to D, through synthesis,¹⁴ which *do* contain a C7'-C8' olefin. Unfortunately neither a sample nor spectral data of morinol I are available, leaving synthesis as the most promising method for determining the correct structure.¹⁵

The putative structure **7** of morinol I was rapidly assembled through a five-step sequence featuring a transmissive olefination (Scheme 2).⁸ Addition of excess vinylmagnesium bromide to the veratraldehyde-derived nitrile **20**,^{9,16} afforded the Z-alkenenitrile **21** that was subjected to a palladium-catalyzed arylation^{14a} with (3,4-dimethoxyphenyl)boronic acid (**22**) to provide **23**. Conventional *i*-Bu₂AlH reduction¹⁷ of nitrile **23**, imine hydrolysis, and aldehyde reduction was irreproducible¹⁸ and gave varying ratios of lignan (7*Z*, 7'*E*)-**7** and the diastereomer (7*E*, 7'*E*)-**7**. Neither (7*Z*, 7'*E*)-**7** nor (7*E*, 7'*E*)-**7** exhibit spectral data matching that of the natural product, although the NMR chemical shifts, such as the ¹H NMR shift for H7, appeared more consistent with the *Z*-configuration of the C7 olefin.

Using the transmissive olefination strategy to prepare *Z*-C7 lignans corresponding to that of morinol I, requires a reproducible, stereoselective alkenenitrile to alkenol conversion. The stereoselective reduction of alkenenitriles to allylic alcohols is challenging because olefin isomerization can occur during the *i*-Bu₂AlH reduction-hydrolysis sequence,¹⁹ in reversed nitrile hydrolysis-reduction sequences,²⁰ and through isomerization of the resulting enal.²¹

After some exploratory forays,²² a stereoselective hydrolysis, acylation, reduction sequence was developed (Scheme 3). The sequence exploits the facile platinum-catalyzed hydrolysis of nitriles²³ (**23** → **24**) and the selective reduction of imides.²⁴ Despite a lack of precedent for the reduction of *alkeneamides*,²⁵ a brief survey of reducing agents and solvent identified LiBH₄ in THF as effective for reducing imide **25** to (7*Z*, 7'*E*)-alkenol **7** without any trace of the 7*E*-diastereomer.²⁶

Having developed a robust method for controlling the stereochemistry of the C7 olefin, (7*Z*, 7'*Z*)-**7** was targeted because the data reported for morinol I suggested either the geometry or position of the 7'*Z*-olefin was incorrect (Scheme 4). Key to the synthesis of (7*Z*, 7'*Z*)-**7** was the serendipitous²⁷ discovery that the trimethylsilylalkene **26**, obtained through the transmissive olefination of **20** with trimethylsilylvinylmagnesium bromide (52%), underwent an efficient trimethylsilyl-iodine interchange with inversion of stereochemistry.²⁸ Treating vinylsilane **26** with *N*-iodosuccinimide in 1:1 dichloromethane:hexafluoroisopropanol²⁹ afforded the *Z*-iodide **27**³⁰ that was subjected to palladium-catalyzed coupling³¹ with (3,4-dimethoxyphenyl)boronic acid (**22**) to afford **28** with retention of configuration. Subjecting **28** to the three-step hydrolysis, acylation, and reduction efficiently provided (7*Z*, 7'*Z*)-**7** with no erosion of olefin configuration.

Although morinol analog (7*Z*, 7'*Z*)-**7** did not exhibit spectral data corresponding to that of the target, during the palladium-catalyzed coupling of **27**, traces of a conjugated dienenitrile were generated which exhibited a ¹H NMR methylene signal very similar to that reported for morinol I (δ 3.47 and 3.55, respectively). Attempts to isomerize the dienes (7*Z*, 7'*Z*)-**28**

and (7Z, 7'Z)-**7** proved fruitless inspiring a new strategy based on the oxidative acetylation³² of **21**. Using the 'original' oxidative acetylation protocol,^{32b} nitrile **21** was smoothly transformed into (7Z, 8'E)-**29** (Scheme 5). Palladium-catalyzed arylation of **29** with (3,4-dimethoxyphenyl)boronic acid (**22**) to afford (7Z, 8'E)-dienenitrile **31** proceeded best by employing the hydrazine ligand **30**.³³ A slight modification of the hydrolysis, imide formation, and reduction was required because the conventional Boc anhydride-DMAP procedure afforded the *bis*-Boc acylimidodicarbonate.³⁴ Deprotonating the intermediate amide with BuLi and adding Boc anhydride afforded the requisite imide that was reduced without incident to the (7Z, 8'E)-alcohol **32**. As a point of comparison, the sequential *i*-Bu₂AlH reduction, imine hydrolysis, and NaBH₄ reduction of nitrile **31** gave a 1:1 mixture of (7Z, 8'E)-**32** and (7E, 8'E)-**32**. Although (7Z, 8'E)-**32** exhibited several ¹H NMR resonances similar to that of morinol, significant spectral differences are evident.

Graphing the ¹H and ¹³C chemical shift differences between morinol I and the lignan diastereomers (7Z, 7'E)-**7**, (7E, 7'E)-**7**, (7E, 7'Z)-**7**, (7Z, 8'E)-**32**, and (7E, 8'E)-**32** highlights the regions having the greatest discrepancy (Figure 3). Large differences in the ¹³C chemical shift exist for C9 and C9' in the pentadiene fragment and for C1 of the aromatic ring.³⁵ The ¹H chemical shift values for the aromatic protons are quite similar whereas H7, H7', and H9' show pronounced differences relative to those reported for morinol I.³⁵ The lack of clear chemical shift correlations of regions within the synthetic lignans compared to values reported for morinol I leave the exact identity of the natural product in doubt.

Morinol-type lignans are readily assembled through sequential transmissive olefinations and palladium-catalyzed couplings. The sequence generates diaryl pentadienes with excellent control over the *E/Z* geometry and features a new strategy for converting *Z*-dienenitriles into *Z*-allylic alcohols. In contrast to the conventional *i*-Bu₂AlH reduction, imine hydrolysis, NaBH₄ reduction of alkenenitriles, the platinum-catalyzed hydrolysis, imide formation, and reduction smoothly generates allylic alcohols without any observable isomerization. The versatility of the transmissive olefination and the new reduction strategy is illustrated in the synthesis of five morinol-type lignans in the quest to determine the structure of the elusive natural product morinol I.

Experimental

(2Z, 4E)-2-(3, 4-Dimethoxybenzylidene)-5-(3,4-dimethoxyphenyl)pent-4-enamide (**24**)

Solid Parkins²³ catalyst [bis(dimethylphosphinous acid-*k*P)dimethylphosphinyl-*k*P-hydridoplatinum(II)] (0.5 mg, 0.0075 mmol) was added to an ethanol/water solution (1:1, 20 mL) of **23** (54.8 mg, 0.15 mmol) and then the reaction mixture was heated to reflux. After 15 h, the solution was cooled, the solvent was evaporated, and then the residue was purified by radial chromatography (70% EtOAc in hexanes) to afford 50.0 mg (87%) of the amide **24** as a white solid (mp: 108–109 °C): IR (solid) 3416, 3338, 2935, 1672, 1518 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz): δ 3.31 (d, *J* = 7.2 Hz, 2H), 3.86 (s, 3H), 3.88 (s, 6H), 3.91 (s, 3H), 5.42 (s, 2H), 6.14 (dt, *J* = 16.0, 7.2 Hz, 1H), 6.47 (d, *J* = 16.0 Hz, 1H), 6.57 (s, 1H), 6.82 (dd, *J* = 8.4, 2.0 Hz, 2H), 6.90–6.97 (m, 4H); ¹³C NMR (CDCl₃, 100 MHz): δ 39.8, 55.9, 56.0, 108.7, 111.0, 111.1, 111.3, 119.3, 121.3, 124.3, 128.3, 130.2, 130.3, 132.3, 135.3, 148.7, 148.9, 149.0, 172.1 ppm; HRMS for C₂₂H₂₅NO₅ [M+Na⁺] calculated: 406.1631 found: 406.1619.

tert-Butyl(2Z,4E)-2-(3,4-dimethoxybenzylidene)-5-(3,4-dimethoxyphenyl)pent-4-enoylcarbamate (**25**)

Solid di-*tert*-butyldicarbonate (43.4 mg, 0.20 mmol) and 4-dimethylaminopyridine (1.2 mg, 0.01 mmol) were added to a rt, CH₂Cl₂ solution (5mL) of **24** (40 mg, 0.10 mmol). After 20 h, the reaction mixture was poured into dichloromethane (10 mL), the phases were

separated, the organic phase was combined and was then washed sequentially with 1M HCl (10 mL) and water (10 mL). The solvent was evaporated and the residue was then purified by radial chromatography (30% EtOAc in hexanes) to afford 35.3 mg (73 %) of imide **25** as a light yellow oil: IR (neat) 2979, 1777, 1601 cm^{-1} ; ^1H NMR (CDCl_3 , 500 MHz): δ 1.43 (s, 9H), 3.31 (d, $J = 7.2$ Hz, 2H), 3.87 (s, 3H), 3.88 (s, 3H), 3.89 (s, 3H), 3.90 (s, 3H), 6.22 (dt, $J = 11.6, 7.2$ Hz, 1H), 6.51 (d, $J = 11.6$ Hz, 1H), 6.51 (s, 1H), 6.80–7.02 (m, 7H); ^{13}C NMR (CDCl_3 , 100 MHz): δ 27.8, 38.4, 55.8, 55.9, 84.6, 108.7, 110.8, 111.0, 111.1, 119.4, 124.0, 128.1, 130.5, 130.7, 132.7, 133.5, 148.6, 148.7, 149.0, 149.3, 170.7 ppm; HRMS for $\text{C}_{27}\text{H}_{33}\text{NO}_7$ $[\text{M}+\text{H}^+]$ calculated: 484.2336, found: 484.2325.

(2Z, 4E)-2-(3,4-Dimethoxybenzylidene)-5-(3,4-dimethoxyphenyl)pent-4-en-1-ol (7Z, 7'E)-7

A THF solution (0.13 mL) of lithium triethylborohydride (0.13 mmol, 1 M) was added to a rt, THF solution (5 mL) of **25** (30 mg, 0.06 mmol). After 2 h, an aqueous solution (10 mL) of 30% H_2O_2 was added. After 30 min, the aqueous phase was extracted with EtOAc (3×10 mL), the combined organic phase was washed with brine, dried (Na_2SO_4), concentrated, and purified by radial chromatography (30% EtOAc in hexanes) to afford 16.0 mg (72%) of alcohol (7Z, 7'E)-7 as a light yellow oil: IR (neat) 3520, 2935, 1598 cm^{-1} ; ^1H NMR (CDCl_3 , 400 MHz): δ 1.59 (broad s, 1H), 3.20 (d, $J = 7.1$ Hz, 2H), 3.88 (s, 6H), 3.89 (s, 3H), 3.91 (s, 3H), 4.34 (s, 2H), 6.20 (dt, $J_1 = 15.8$ Hz, $J_2 = 7.1$ Hz, 1H), 6.47 (d, $J = 15.8$ Hz, 1H), 6.50 (s, 1H), 6.84 (d, $J = 8.3$ Hz, 1H), 6.87 (d, $J = 8.1$ Hz, 1H), 6.88 (d, $J = 8.3$ Hz, 1H), 6.89 (s, 1H), 6.95 (dd, $J_1 = 8.1$ Hz, $J_2 = 2.0$ Hz, 1H), 6.98 (d, $J = 2.0$ Hz, 1H); ^{13}C NMR (CDCl_3 , 100 MHz): δ 39.5, 55.8, 55.9, 55.9, 61.3, 108.6, 110.9, 111.1, 112.0, 119.1, 121.2, 126.0, 129.4, 129.8, 130.4, 131.7, 138.5, 148.1, 148.5, 148.6, 149.0 ppm; HRMS for $\text{C}_{22}\text{H}_{26}\text{O}_5$ $[\text{M}+\text{Na}^+]$ calculated: 393.1678, found: 393.1696.

(2Z, 4E)-2-(3, 4-Dimethoxybenzylidene)-5-(trimethylsilyl)pent-4-enenitrile (26)

Neat 1, 2-dibromoethane (0.01 mL, 0.07 mmol) was added to a suspension of Mg (22.4 mg, 0.89 mmol) in cold (0°C) THF (0.8 mL). Neat (*E*)-(2-(trimethylsilyl)vinyl) bromide (0.09 mL, 0.69 mmol) was added dropwise and after 1 h at 0°C the THF solution of the resulting Grignard reagent was added to a -20°C , THF solution (3 mL) of 2-((3, 4-dimethoxyphenyl) (hydroxy)methyl) acrylonitrile **20**^{9,16} (50 mg, 0.23 mmol). After 3 h, the reaction mixture was poured into aqueous, saturated NH_4Cl (2 mL). The aqueous phase was extracted with EtOAc (3×10 mL), the combined organic phase was washed with brine, dried (Na_2SO_4), concentrated and purified by radial chromatography (15% EtOAc in hexanes) to afford 36.8 mg (52%) of nitrile **26** as a light yellow oil: IR (neat) 2954, 2206, 1600 cm^{-1} ; ^1H NMR (CDCl_3 , 500 MHz): δ -0.01 (s, 9H), 3.16 (d, $J = 6.6$ Hz, 2H), 3.92 (s, 3H), 3.94 (s, 3H), 5.88 (d, $J = 18.0$ Hz, 1H), 6.04 (dt, $J = 18.0, 6.6$ Hz, 1H), 6.84 (s, 1H), 6.87 (d, $J = 7.8$ Hz, 1H), 7.19 (dd, $J = 7.8, 1.8$ Hz, 1H), 7.56 (d, $J = 1.8$ Hz, 1H); ^{13}C NMR (CDCl_3 , 100 MHz): δ -1.32, 42.7, 55.9, 106.2, 110.1, 110.7, 119.4, 123.3, 126.6, 134.7, 140.3, 143.9, 148.8, 150.5 ppm; HRMS for $\text{C}_{17}\text{H}_{23}\text{NO}_2\text{Si}$: $[\text{M}+\text{H}^+]$ calculated 302.1577, found 302.1563.

(2Z, 4Z)-2-(3,4-Dimethoxybenzylidene)-5-iodopent-4-enenitrile (27)

Solid *N*-iodo succinimide (146.3 mg, 0.65 mmol) was added to a 0°C 1,1,1,3,3,3-hexafluoroisopropanol and dichloromethane (1:1) solution (1.6 mL) of **26** (130 mg, 0.43 mmol). After 10 min, the reaction mixture was poured into an aqueous, saturated NH_4Cl solution (2 mL). The aqueous phase was extracted with EtOAc (3×10 mL), the combined organic phase was washed with brine, dried (Na_2SO_4), concentrated, and purified by radial chromatography (15% EtOAc in hexanes) to afford 125 mg (82%) of nitrile **27** as a light yellow oil. IR (neat) 2934, 2206, 1597 cm^{-1} ; ^1H NMR (CDCl_3 , 500 MHz): δ 3.26 (d, $J = 6.6$ Hz, 2H), 3.93 (s, 3H), 3.94 (s, 3H), 6.39 (dt, $J = 7.6, 7.6$ Hz, 1H), 6.57 (dt, $J = 7.6$ Hz, 1.4 Hz, 1H), 6.89 (d, $J = 8.4$ Hz, 1H), 6.95 (s, 1H), 7.21 (dd, $J = 8.4, 2.4$ Hz, 1H), 7.52 (d, $J = 2.4$ Hz, 1H); ^{13}C NMR (CDCl_3 , 100 MHz): δ 40.8, 55.9 (2), 86.6, 104.0, 110.2, 110.7,

119.2, 123.4, 126.3, 135.6, 144.3, 148.8, 150.7 ppm; HRMS for $C_{14}H_{14}NO_2I$ [$M+Na^+$] calculated: 377.9967, found: 377.9944.

(2Z, 4Z)-2-(3,4-Dimethoxybenzylidene)-5-(3,4-dimethoxyphenyl)pent-4-enitrile (28)

Solid (3,4-dimethoxyphenyl) boronic acid (87.8 mg, 0.46 mmol), palladium acetate (14.0 mg, 0.06 mmol) and triphenyl phosphine (32.5 mg, 0.12 mmol) were added to a rt, THF solution (8 mL) of **27** (100.0 mg, 0.31 mmol). After 12 h, the reaction mixture was poured into water (2 mL). The aqueous phase was extracted with EtOAc (3×10 mL), the combined organic phase was washed with brine, dried (Na_2SO_4), concentrated, and purified by radial chromatography (30% EtOAc in hexanes) to afford 88.3 mg (78%) of nitrile **28** as a light yellow oil: IR (neat) 2931, 2206 cm^{-1} ; 1H NMR ($CDCl_3$, 500 MHz): δ 3.39 (d, $J = 7.8$ Hz, 2H), 3.89 (s, 3H), 3.90 (s, 3H), 3.92 (s, 3H), 3.93 (s, 3H), 5.72 (dt, $J = 11.4, 7.2$ Hz, 1H), 6.67 (d, $J = 11.4$ Hz, 1H), 6.83 (s, 1H), 6.85–6.89 (m, 3H), 6.91 (s, 1H), 7.19 (dd, $J = 8.4, 1.8$ Hz, 1H), 7.53 (d, $J = 1.8$ Hz, 1H); NOESY correlations between δ 5.72 and 6.67 established the Z-configuration of the disubstituted olefin; ^{13}C NMR ($CDCl_3$, 100 MHz): δ 34.7, 55.9 (2), 106.8, 110.3, 110.8, 111.0, 111.9, 119.5, 121.1, 123.2, 124.9, 126.6, 129.3, 132.5, 143.6, 148.3, 148.7, 149.0, 150.7 ppm; HRMS for $C_{22}H_{23}NO_4$ [$M+Na^+$] calculated: 388.1525, found: 388.1512.

(2Z, 4Z)-2-(3, 4-Dimethoxybenzylidene)-5-(3, 4-dimethoxyphenyl)pent-4-enamide (i)

Solid Parkins²³ catalyst [bis(dimethylphosphinous acid- kP)dimethylphosphinyl- kP -hydridoplatinum(II)] (0.6 mg, 0.01 mmol) was added to an ethanol/water solution (1:1, 20 mL) of **28** (80 mg, 0.22 mmol) and then the reaction was heated to reflux. After 15 h, the solvent was evaporated and the residue was purified by radial chromatography (70% EtOAc in hexanes) to afford 95.1 mg (92%) of amide **i** as a white solid (mp: 101–102 °C): IR (solid) 3411, 3339, 2934, 2836, 1677, 1601 cm^{-1} ; 1H NMR ($CDCl_3$, 400 MHz): δ 3.48 (d, $J = 7.6$ Hz, 2H), 3.88 (s, 3H), 3.90 (s, 3H), 3.91 (s, 3H), 3.92 (s, 3H), 5.43 (s, 2H), 5.75 (dt, $J = 11.6, 7.6$ Hz, 1H), 6.59 (s, 1H), 6.61 (d, $J = 11.6$ Hz, 1H), 6.80–7.00 (m, 6H); ^{13}C NMR ($CDCl_3$, 100 MHz): δ 34.1, 55.9 (2), 111.0, 111.3, 111.9, 121.2 (2), 126.3, 128.3, 129.8 (2), 131.4, 135.2, 148.1, 148.7, 148.8, 172.3 ppm; HRMS for $C_{22}H_{25}NO_5$ [$M+Na^+$] calculated: 406.1631, found: 406.1618.

tert-Butyl((2Z,4Z)-2-(3,4-dimethoxybenzylidene)-5-(3,4-dimethoxyphenyl)pent-4-enoyl)carbamate (ii)

Solid di-*tert*-butyl dicarbonate (136.8 mg, 0.63 mmol) and 4-dimethylamino pyridine (2.9 mg, 0.02 mmol) were added to a CH_2Cl_2 , rt, solution (5 mL) of **i** (90 mg, 0.24 mmol). After 20 h the reaction mixture was poured into dichloromethane (10 mL) and washed sequentially with 1M HCl (10 mL) and water (10 mL). The solvent was evaporated and the residue was then purified by radial chromatography (30% EtOAc in hexanes) to afford 88.3 mg (76 %) of imide **ii** as a light yellow oil: IR (neat) 3296, 2930, 1766, 1686 cm^{-1} ; 1H NMR ($CDCl_3$, 500 MHz): δ 1.38 (s, 9H), 3.45 (d, $J = 7.8$ Hz, 2H), 3.85 (s, 3H), 3.88 (s, 3H), 3.89 (s, 3H), 3.91 (s, 3H), 5.73 (dt, $J = 11.4, 7.2$ Hz, 1H), 6.61 (d, $J = 6.0$ Hz, 1H), 6.62 (d, $J = 6.0$ Hz, 1H), 6.80–6.92 (m, 7H); ^{13}C NMR ($CDCl_3$, 100 MHz): δ 27.8, 33.6, 55.8, 55.9 (2), 82.7, 110.7, 110.8, 110.9, 111.6, 121.2, 125.6, 127.8, 129.6, 131.8, 134.6, 148.1, 148.6, 148.8, 149.0, 149.1 ppm; HRMS for $C_{27}H_{33}NO_7$ [$M+Na^+$] calculated: 506.2155, found: 506.2155.

(1Z, 4Z)-1,5-Bis(3,4-dimethoxyphenyl)penta-1,4-dien-2-ol (7Z, 7'Z)-7

A THF solution (0.34 mL) of lithium triethylborohydride (0.34 mmol, 1 M) was added to a rt, THF solution (5 mL) of **ii** (80 mg, 0.17 mmol). After 2 h, an aqueous 30% solution (10 mL) of H_2O_2 was added. After 30 min, the aqueous phase was extracted with EtOAc (3×10

mL), the combined organic phase was washed with brine, dried (Na₂SO₄), concentrated and purified by radial chromatography (30% EtOAc in hexanes) to afford 43.4 mg (69%) of alcohol (7Z, 7'Z)-**7** as a light yellow oil: IR (neat) 3517, 2925, 1514 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 1.28 (s, 1H), 3.36 (d, *J* = 7.6 Hz, 2H), 3.88 (s, 6H), 3.89 (s, 3H), 3.91 (s, 3H), 4.35 (s, 2H), 5.82 (dt, *J*₁ = 11.6 Hz, *J*₂ = 7.6 Hz, 1H), 6.51 (s, 1H), 6.66 (d, *J* = 11.6 Hz, 1H), 6.86 (d, *J* = 7.2 Hz, 1H), 6.87 (d, *J* = 7.2 Hz, 1H), 6.89 (s, 1H), 6.86 (d, *J* = 7.2 Hz, 1H), 6.93 (s, 1H), 6.94 (d, *J* = 7.2 Hz, 1H); ¹³C NMR (CDCl₃, 400 MHz): δ 34.7, 55.9 (3), 77.2, 110.9, 111.9, 112.0, 121.1, 121.2, 128.0, 129.0, 130.0, 131.0, 138.7, 148.0 ppm; HRMS for C₂₂H₂₆O₅ [M+Na⁺] calculated: 393.1678, found: 393.1691.

(2E,4Z)-4-cyano-5-(3,4-dimethoxyphenyl)penta-2,4-dien-1-yl acetate (**29**)

Solid 1, 4 benzoquinone (37.7 mg, 0.35 mmol), palladium acetate (4.0 mg, 0.02 mmol) and 4Å MS were added to a DMSO/AcOH solution (1:1, 5 mL) of **21** (40 mg, 0.17 mmol). The reaction was maintained at 40 °C under an air atmosphere using an air-filled balloon to maintain a slight positive pressure. After 72 h the reaction mixture was poured into EtOAc (10 mL), the phases were separated, the organic phase was washed with water (3 × 5 mL), dried (Na₂SO₄), concentrated, and purified by radial chromatography (20% EtOAc in hexanes) to afford 203 mg (67%) of nitrile **29** as a light yellow oil: IR (neat) 2254 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 2.14 (s, 3H), 3.95 (s, 3H), 3.96 (s, 3H), 4.74 (d, *J* = 6.0 Hz, 2H), 6.25 (dt, *J* = 15.8 Hz, 6.0 Hz, 1H), 6.41 (d, *J* = 15.8 Hz, 1H), 6.74 (s, 1H), 6.91 (d, *J* = 8.6 Hz, 1H), 7.01 (s, 1H), 7.27 (dd, *J* = 8.6 Hz, 2.2 Hz, 1H), 7.63 (d, *J* = 2.2 Hz, 1H); ¹³C NMR (CDCl₃, 400 MHz): δ 21.0, 56.0, 63.8, 107.0, 110.6, 110.9, 116.2, 116.8, 124.5, 126.4, 127.0, 130.8, 144.4, 149.1, 151.4, 170.7 ppm; HRMS for C₁₆H₁₇NO₄K [M+K⁺] calculated: 326.0789, found: 326.0820.

(2Z,3E)-2-(3,4-dimethoxybenzylidene)-5-(3,4-dimethoxyphenyl)pent-3-enenitrile (**31**)

Solid (3,4-dimethoxyphenyl)boronic acid (115 mg, 0.63 mmol) was added to a rt, DMF (1.5 mL) and H₂O (0.5 mL) solution of **29** (150 mg, 0.522 mmol), K₂CO₃ (144 mg, 1.044 mmol), Pd(OAc)₂ (2.33 mg, 0.01 mmol), and ligand (*N,N'E,N,N'E*)-*N,N'*-(ethane-1,2-diylidene)bis(piperidin-1-amine)³⁶ (2.31 mg, 0.01 mmol). After 1 h, the mixture was diluted with EtOAc and H₂O (10 mL, 1:1). The organic layer was separated, the aqueous phase was extracted with EtOAc (2 × 10 mL), the combined organic phase was washed with brine, dried (Na₂SO₄), concentrated, and purified by radial chromatography (30% EtOAc in hexanes) to afford 116 mg (61%) of **31** as a white solid (mp 102–104 °C): IR: 1025, 1144, 1265, 1514, 1554, 1627, 2214, 2836, 2934 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 3.49 (d, *J* = 7.0 Hz, 2H), 3.88 (s, 3H), 3.89 (s, 3H), 3.92 (s, 3H), 3.94 (s, 3H), 6.10 (d, *J* = 15.3 Hz, 1H), 6.38 (dt, *J* = 15.3, 6.8 Hz, 1H), 6.72–6.77 (m, 2H), 6.83–6.89 (m, 3H), 7.22 (dd, *J* = 8.4, 2.3 Hz, 1H), 7.58 (d, *J* = 2.3 Hz, 1H) ppm; ¹³C NMR (CDCl₃, 400 MHz): δ 38.4, 55.9, 56.0, 108.1, 110.5, 110.9, 111.4, 112.0, 117.2, 120.7, 123.9, 126.8, 128.4, 131.6, 133.9, 142.2, 147.7, 149.0, 150.9 ppm; HRMS for C₂₂H₂₃NO₄ [M+Na⁺] calculated: 388.1519, found: 388.1521.

(2Z,4E)-2-(3,4-dimethoxybenzylidene)-5-(3,4-dimethoxyphenyl)pent-4-enamide (**iii**)

Solid Parkins²³ catalyst (bis(dimethylphosphinous acid-*k*P)dimethylphosphinyl-*k*P-hydridoplatinum(II)) (4.5 mg, 0.5 mol%, 0.01 mmol) was added to an ethanol-water (1:1, 20 mL) solution of **31** (75 mg, 0.21 mmol) and then the reaction was heated to reflux. After 15 h, the solvent was evaporated and the residue was purified by radial chromatography (70% EtOAc in hexanes) to afford 74 mg (94%) of the amide **iii** as a white solid (mp: 144–146 °C): IR: 3412, 3338, 1677 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 3.45 (d, *J* = 4.8 Hz, 2H), 3.86 (s, 3H), 3.87 (s, 3H), 3.88 (s, 6H), 5.56 (br, s, 1H), 5.60 (br, s, 1H), 6.08–6.14 (m, 2H), 6.39 (s, 2H), 6.72–6.75 (m, 2H), 6.80–6.82 (m, 2H), 6.99–7.04 (m, 2H) ppm; ¹³C NMR (CDCl₃, 400 MHz): δ 38.8, 55.8, 55.9, 56.0, 111.0, 111.2, 111.3, 112.1, 120.7, 121.8, 128.1,

129.5, 130.2, 132.1, 135.0, 147.5, 148.8, 148.9, 149.1, 171.5 ppm; HRMS for $C_{22}H_{25}NO_5$ $[M+Na^+]$ calculated: 406.1625, found: 406.1632.

***tert*-butyl ((2*Z*,3*E*)-2-(3,4-dimethoxybenzylidene)-5-(3,4-dimethoxyphenyl)pent-3-enoyl)carbamate (**iv**)**

A cyclohexane solution of BuLi (2.0 M, 0.156 mmol) was added, drop-wise, to a $-78\text{ }^{\circ}\text{C}$, THF (3 mL) solution of **iii** (60 mg, 0.156 mmol). After 1 h, a THF (1.0 mL) solution of di-*tert*-butyl dicarbonate (34 mg, 0.156 mmol) was added, and the reaction mixture was then allowed to warm slowly to room temperature. After 16 h saturated, aqueous ammonium chloride (3 mL) was added followed by H_2O (5 mL). The organic layer was separated, the aqueous phase was extracted with EtOAc ($2 \times 10\text{ mL}$), and the combined organic phase was washed with brine, dried (Na_2SO_4), concentrated, and purified by radial chromatography (50% EtOAc in hexanes) to afford 52 mg (68%) of **iv** as a pale yellow gummy liquid: IR: 3280, 2934, 1767, cm^{-1} ; 1H NMR ($CDCl_3$, 400 MHz): δ 1.39 (s, 9H), 3.44 (d, $J = 5.8\text{ Hz}$, 2H), 3.85 (s, 3H), 3.87 (s, 3H), 3.88 (s, 3H), 3.89 (s, 3H), 5.94–6.0 (m, 1H), 6.13 (d, $J = 15.6\text{ Hz}$, 1H), 6.44 (s, 1H), 6.71–6.74 (m, 2H), 6.79–6.82 (m, 2H), 6.90–6.93 (m, 2H), 7.30 (s, 1H) ppm; ^{13}C NMR ($CDCl_3$, 400 MHz): δ 27.8, 38.8, 55.83, 55.89, 55.92, 55.98, 56.0, 82.9, 110.7, 111.1, 111.3, 112.1, 120.7, 132.0, 134.3, 136.0, 147.6, 148.9, 149.1, 149.3 ppm; HRMS for $C_{27}H_{33}NO_7 Na$ $[M+Na^+]$ calculated: 506.2149, found: 506.2142.

(2*Z*,3*E*)-2-(3,4-dimethoxybenzylidene)-5-(3,4-dimethoxyphenyl)pent-3-en-1-ol (7*Z*, 9'*E*)-32****

A THF solution (5 mL) of lithium triethylborohydride (0.17 mL, 0.17 mmol) was added to a $0\text{ }^{\circ}\text{C}$, THF solution (3 mL) of **iv** (40 mg, 0.083 mmol) and then the solution was allowed to warm slowly to rt. After 2 h, an aqueous 30% solution of H_2O_2 (6 mL) was added. After 30 min, the aqueous phase was extracted with EtOAc ($3 \times 10\text{ mL}$), the combined organic phase was washed with brine, dried (Na_2SO_4), concentrated and purified by radial chromatography (30% EtOAc in hexanes) to afford 19 mg (62%) of (7*Z*, 9'*E*)-**32** as a light yellow oil: IR: 1023, 1138, 1232, 1258, 1511, 1593, 1709, 2835, 2932, 3510 cm^{-1} ; 1H NMR ($CDCl_3$, 400 MHz): δ 3.47 (d, $J = 6.5\text{ Hz}$, 2H), 3.87 (s, 3H), 3.88 (s, 3H), 3.89 (s, 3H), 3.90 (s, 3H), 4.47 (*br*, d, 2H), 6.11 (dt, $J_1 = 15.8\text{ Hz}$, $J_2 = 6.5\text{ Hz}$, 1H), 6.20 (d, $J = 15.8\text{ Hz}$, 1H), 6.58 (s, 1H), 6.74 (d, $J = 2.0\text{ Hz}$, 1H), 6.77 (dd, $J_1 = 8.0\text{ Hz}$, $J_2 = 2.0\text{ Hz}$, 1H), 6.82 (d, $J = 8.0\text{ Hz}$, 1H), 6.86 (d, $J = 8.3\text{ Hz}$, 1H), 6.97 (dd, $J_1 = 8.3\text{ Hz}$, $J_2 = 2.0\text{ Hz}$, 1H), 7.00 (d, $J = 2.0\text{ Hz}$, 1H) ppm; ^{13}C NMR ($CDCl_3$, 400 MHz): δ 39.1, 55.87, 55.90, 55.92, 55.98, 58.3, 111.0, 111.3, 112.0, 112.2, 120.5, 121.7, 129.1, 129.6, 132.7, 133.1, 133.3, 136.4, 147.5, 148.5, 148.7, 149.0 ppm; HMBC correlation of the 1H NMR hydroxymethyl signal at δ 3.47 with the olefinic ^{13}C signals at δ 133.3, 136.4 confirm that the olefins are conjugated; HRMS for $C_{22}H_{26}O_5Na$ $[M+Na^+]$ calculated: 393.1672, found: 393.1697.

(2*E*,3*E*)-2-(3,4-dimethoxybenzylidene)-5-(3,4-dimethoxyphenyl)pent-3-en-1-ol (7*Z*, 9'*E*)-32** and (7*E*, 9'*E*)-**32****

A cyclohexane solution of diisobutylaluminum hydride (1.0 M, 0.58 mmol) was added drop-wise to a $-78\text{ }^{\circ}\text{C}$, toluene (4 mL) solution of **31** (100 mg, 0.274 mmol). The cooling bath was removed and the reaction allowed to slowly warm to rt. After 3 h the reaction mixture was cooled to $-78\text{ }^{\circ}\text{C}$ and ethanol (1 mL) and aqueous acetic acid (50%, 1 mL) were added sequentially. After 15 min. the solution was allowed to warm to rt, the organic layer was separated, the aqueous phase was extracted with EtOAc ($2 \times 10\text{ mL}$), the combined organic phase was washed with water, aqueous $NaHCO_3$, and brine, and then dried (Na_2SO_4), and concentrated to give the corresponding aldehyde (96 mg). The crude aldehyde (96 mg) was dissolved in methanol (7 mg, 0.30 mmol) at room temperature and solid $NaBH_4$ was then added portion-wise. After 15 min. saturated, aqueous ammonium chloride (2 mL) was added, followed by water. The crude mixture was extracted with EtOAc ($2 \times 10\text{ mL}$), the combined organic phase was washed with brine, dried (Na_2SO_4), concentrated, and purified

by radial chromatography (35% EtOAc in hexanes) to afford 57 mg (56%) of a 1:1 mixture of alcohols (7*Z*, 9'*E*)-**32** and (7*E*, 9'*E*)-**32** as a pale yellow oily liquid. For (7*E*, 9'*E*)-**32**: IR: 3504, 2933, 1592 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 3.42 (d, *J* = 6.9 Hz, 2H), 3.86 (s, 9H), 3.90 (s, 3H), 4.44 (br, d, *J* = 2.8 Hz, 2H), 6.12 (dt, *J*₁ = 16.2 Hz, *J*₂ = 6.9 Hz, 1H), 6.56 (d, *J* = 16.2 Hz, 1H), 6.58 (s, 1H), 6.71 (s, 1H), 6.73 (d, *J* = 8.5, 1H), 6.82 (d, *J* = 8.5, 1H), 6.84 (d, *J* = 8.6 Hz, 1H), 6.86 (d, *J* = 8.6 Hz, 1H), 6.86 (s, 1H) ppm; ¹³C NMR (CDCl₃, 400 MHz): δ 39.4, 55.8, 55.9, 55.9, 56.0, 110.86, 111.3, 111.9, 112.6, 120.4, 122.2, 126.9, 128.2, 129.7, 131.3, 132.6, 136.1, 147.5, 148.2, 149.0 ppm; HRMS for C₂₂H₂₆O₅Na [M+Na⁺] calculated: 393.1672, found: 393.1704.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Financial support from the National Institutes of Health (2R15AI051352-03) is gratefully acknowledged.

References

1. Fleming FF, Yao L, Ravikumar PC, Funk L, Shook BC. J Med Chem. 2010; 53:7902. [PubMed: 20804202]
2. Fleming FF. Nat Prod Rep. 1999; 16:597.
3. De Clercq E. Emerging anti-HIV drugs. Expert Opin Emerging Drugs. 2005; 10:241.
4. Das K, Lewi PJ, Hughes SH, Arnold E. Prog Biophys Mol Bio. 2005; 88:209. [PubMed: 15572156]
5. Ruchelman AL, Man HW, Chen R, Liu W, Lu L, Cedzik D, Zhang L, Leisten J, Collette A, Narla RK, Raymon HK, Muller GW. Bioorg Med Chem. 2011; 19:6356. [PubMed: 21955454]
6. Ishihara H, Martin BL, Brautigan DL, Kiraki H, Ozaki H, Kato Y, Fusetani N, Watabe S, Hashimoto K, Uemura D, Hartshorne DJ. Biochem Biophys Res Commun. 1989; 159:871. [PubMed: 2539153]
7. (a) Fleming FF, Shook BC. J Org Chem. 2002; 67:3668. [PubMed: 12027678] (b) Mauzé B, Miginiac L. Synth Commun. 1992; 22:2229. (c) Takyangi H, Kitano Y, Morinaka Y. Tetrahedron Lett. 1990; 31:3317. (d) Matsuda I, Okada H, Izumi Y. Bull Chem Soc Jpn. 1983; 56:528.
8. Fleming FF, Liu W, Yao L, Pitta B, Purzycki M, Ravikumar PC. Eur J Org Chem. 2011:6843.
9. Coelho F, Almeida WP, Veronese D, Mateus CR, Silva Lopes EC, Rossi RC, Silveira GPC, Pavam CH. Tetrahedron. 2002; 58:7437.
10. The A-value is only 0.2 kcal mol⁻¹: Eliel, Ernest L.; Wilen, Samuel H.; Mander, Lewis N. Stereochemistry of Organic Compounds. WileyNY1994:696–7.
11. (a) Zhu Y, Lu ZP, Xue CB, Wu WS. Helv Chim Acta. 2009; 92:536. (b) Su BN, Takaishi Y, Duan HQ, Chen B. J Nat Prod. 1999; 62:1363. [PubMed: 10543893]
12. Su BN, Takaishi Y, Kusumi T. Tetrahedron. 1999; 55:14571.
13. Morikawa T, Ando S, Matsuda H, Kataoka S, Muraoka O, Yoshikawa M. Chem Pharm Bull. 2005; 53:625. [PubMed: 15930771]
14. (a) Ogura K, Sugahara T, Maruyama M, Akiyama K, Yamauchi S. Biosci Biotechnol Biochem. 2010; 74:1641. [PubMed: 20699576] (b) Yamauchi S, Sugahara T, Akiyama K, Maruyama M. J Nat Prod. 2007; 70:549. [PubMed: 17302455] (c) Yamauchi S, Uno H. Org Biomol Chem. 2003:1323. [PubMed: 12929662]
15. For a review of natural products with revised identities see: Nicolaou KC, Snyder SA. Angew Chem, Int Ed. 2005; 44:1012.
16. Zhong W, Liu Y, Guo B. Heterocycles. 2009; 78:3053.
17. Winterfeldt E. Synthesis. 1975; 10:617.

18. Monitoring the reaction revealed that the isomerization occurs during hydrolysis of the intermediate imine. Use of different acids (HCl, TsOH, Citric acid) and different acid concentrations did not identify reproducible conditions for the hydrolysis.
19. Díez D, Núñez MG, Moro RF, Lumeras W, Marcos IS, Basabe P, Urones JG. *Synlett*. 2006:939.
20. Yoneda R, Harusawa S, Kurihara T. *J Chem Soc, Perkin Trans I*. 1988:3163.
21. (a) Henderson AP, Bleasdale C, Delaney K, Lindstrom AB, Rappaport SM, Waidyanatha S, Watson WP, Golding BT. *Bioorg Chem*. 2005; 33:363. [PubMed: 16005934] (b) Xiao XY, Prestwich GD. *Synth Commun*. 1990; 20:3125. (c) Trost BM, Livingston RC. *J Am Chem Soc*. 1995; 117:9586.
22. Neither $\text{LiAl}(\text{OEt})_3\text{H}^a$ or various Raney-nickel mediated partial reduction procedures^{b-d} were effective. Brown HC, Garg CP. *J Am Chem Soc*. 1964; 86:1085. Khai BT, Arcelli A. *J Org Chem*. 1989; 54:949. van Es T, Staskun B. *J Chem Soc*. 1965:5775. Backeberg OG, Staskun B. *J Chem Soc*. 1962:3961.
23. Ghaffar T, Parkins AW. *J Mol Catal A: Chem*. 2000; 160:249.
24. As a representative example see: Campbell CL, Hassler C, Ko SS, Voss ME, Guaciaro MA, Carter PH, Cherney RJ. *J Org Chem*. 2009; 74:6368. [PubMed: 19588919]
25. For the reduction of primary amides via the bis-Boc acylimidodicarbonates see: Tagnarsson U, Grehn L, Monteiro LS, Maia HLS. *Synlett*. 2003:2386. For the related reduction of a saturated N-unsubstituted Boc acylcarbonate see: Nevill CR Jr, Angell PT. *Tetrahedron Lett*. 1998; 39:5671.
26. LiBH_4 in THF was found to be far superior to the use of NaBH_4 in a variety of solvents.
27. Originally prepared for a Suzuki-Miyaura cross coupling of **25** which proved intractable: Farinola GM, Fiandanesi V, Mazzone L, Naso F. *J Chem Soc, Chem Commun*. 1995:2523.
28. Miesch M, Miesch-Gross L, Franck-Neuman M. *Tetrahedron*. 1997; 53:2111.
29. Ilardi EA, Stivala CE, Zakarian A. *Org Lett*. 2008; 10:1727. [PubMed: 18386904]
30. Performing the reaction under dilute conditions affords small amounts of the E-diastereomer whereas the use of CH_3CN as the solvent was unselective: Stamos DP, Taylor AG, Kishi Y. *Tetrahedron Lett*. 1996; 37:8647.
31. Leyva A, Blum FE, Hewitt PR, Ley SV. *Tetrahedron*. 2008; 64:2348.
32. (a) Vermeulen NA, Delcamp JH, White MC. *J Am Chem Soc*. 2010; 132:11328. (b) Chen MS, White MC. *J Am Chem Soc*. 2004; 126:1346. [PubMed: 14759185]
33. Mino T, Kajiwaru K, Shirae Y, Sakamoto M, Fujita T. *Synlett*. 2008:2711.
34. Attempts to reduce the *bis*-Boc acylimidodicarbonate²⁵ to the allylic alcohol were plagued by numerous side products.
35. The shift values for C7' and C9' for (7Z, 8'E)-**32** and (7E, 8'E)-**32** are interposed in the table to accommodate the olefin transposition. The greatest points of difference in the chemical shift data are illustrated below with a full comparison provided in the Supporting Information on page S35.

	H7	H7'	C9	C9'
6.24	3.55	64.2	127.2
(7Z, 7'E)- 7	6.50	3.20	61.3	121.2
(7E, 7'E)- 7	6.65	3.42	67.2	121.0
(7Z, 7'Z)- 7	6.51	3.36	77.2	121.2
(7Z, 9'E)- 32	6.58	3.47	58.3	121.7
(7E, 9'E)- 32	6.58	3.42	65.4	122.1

36. Mino T, Kajiwara K, Shirae Y, Sakamoto M, Fujita T. *Synlett*. 2008:2711.

Figure 1.
Bioactive Alkenenitriles.

Figure 2.
Representative Morinol-Type Lignans.

Figure 3.
 ^{13}C (top) and ^1H NMR (bottom) $\Delta\delta$ for Morinol Analogs³⁵

Scheme 1.
Transmissive Olefination Route to Z-Alkenenitriles

Scheme 2.
Transmissive Olefination Route to "Morinol I".

Scheme 3.
Stereoselective Alkenenitrile to Hydroxymethyl Conversion.

Scheme 4.
Invertive Trimethylsilyl-Iodine Route to (7Z, 7'Z)-7

Scheme 5.
Transmissive Olefination Route to the Conjugated Morinol Analog **32**.